An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

Summary

This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS.

Timeline

Start

2013-03

Primary completion

2014-10

Completion

2015-01

Drugs

Indications